Polytherapy with two or more ASDs, the use of mTOR inhibitors, TSC manifestations, such as epilepsy, structural brain disorders, psychiatric and cardiac disease, and disability, were all associated with increased total costs according to the univariate analyses, which are detailed in Table 6. This evidence concerns the gene MTOR and heart disorder.